Latest From Codexis Inc.
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Codexis Inc.
- Senior Management
John Nicols, Pres. & CEO
Ross Taylor, SVP, CFO
Jim Lalonde, PhD, SVP, R&D
Laurie Heilmann, SVP, Bus. Dev. & Mktg.
- Contact Info
Phone: (650) 421-8100
200 Penobscot Dr.
Redwood City, CA 94063
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.